Inactive Instrument

Protea Biosciences Group, Inc

Equities

Healthcare Facilities & Services

Protea Biosciences Group, Inc. Announces Marketing Partnership with MatTek Corp

January 10, 2017 at 08:30 am

Protea Biosciences Group Inc. announced that the company has entered into a co-marketing agreement with MatTek Corporation, which allows Protea to include MatTek’s human cell based in vitro tissue models with Protea’s proprietary molecular imaging services.

Latest news about Protea Biosciences Group, Inc

Summit Resources Inc cancelled the acquisition of all assets of Protea Biosciences Group, Inc (OTCPK:PRGB.Q).	18-07-25	CI
Protea Biosciences, Inc. Emerged from Bankruptcy	18-02-01	CI
Motion for Asset Sale Approved for Protea Biosciences, Inc.	18-01-25	CI
Final DIP Financing Approved for Protea Biosciences, Inc.	18-01-19	CI
Bidding Procedure Approved for Protea Biosciences, Inc.	17-12-13	CI
Interim DIP Financing Approved for Protea Biosciences, Inc.	17-12-12	CI
Protea Biosciences Group, Inc Announces the Resignation of David Halverson as President	17-12-05	CI
Motion for Asset Sale Filed by Protea Biosciences, Inc.	17-12-05	CI
Motion for Joint Administration Approved for Protea Biosciences, Inc.	17-12-04	CI
Summit Resources Inc entered into asset purchase agreement to acquire all assets of Protea Biosciences Group, Inc (OTCPK:PRGB.Q) for $1.3 million.	17-12-04	CI
Protea Biosciences, Inc. Announces Resignation of Patrick Gallagher as Member of the Board	17-12-01	CI
Motion for Joint Administration Filed by Protea Biosciences, Inc.	17-12-01	CI
Protea Biosciences, Inc. Filed for Bankruptcy	17-11-30	CI
Protea Biosciences Group, Inc Announces Resignation of Stephen Turner as Chief Executive Officer and Chairman of the Board	17-10-26	CI
Protea Biosciences Group, Inc. Announces Clinical Assay Development Plans	17-10-10	CI
Protea Biosciences Group, Inc. Announces Resignation of Steve Anoline as Member of the Board	17-10-04	CI
Protea Biosciences Group, Inc Expands Clinical Study for New Melanoma Test	17-08-22	CI
Protea Biosciences Group, Inc. Enters into Collaboration Research Agreement with Vaccine and Immunotherapy Center	17-08-08	CI
Maged Shenouda Resigns as Director of Protea Biosciences Group, Inc	17-06-28	CI
Protea Biosciences Group, Inc Introduces New Molecular Imaging Technology	17-06-21	CI
Protea and Proteos Announce Co-Marketing Agreement	17-05-04	CI
Protea Biosciences Group, Inc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016	17-04-18	CI
Protea Biosciences Group, Inc Auditor Raises 'Going Concern' Doubt	17-04-13	CI
Protea Biosciences Group, Inc announced that it has received $2.72708 million in funding	17-03-27	CI
Protea Announces Renewal of Molecular Information Services Collaboration with Protein Metrics	17-01-19	CI

Chart Protea Biosciences Group, Inc

Duration

Period

More charts

Company Profile

Protea Biosciences Group, Inc. is a molecular information company. The Company is engaged in developing and commercializing life science technologies, products and services to identify the molecules that are produced by living cells and all life forms. It also offers a platform technology, Laser Ablation Electrospray Ionization (LAESI), which enables the direct analysis, mapping and display of molecular information in living cells and tissue samples. The Company's commercial development is centered in three business lines: Molecular Information Services, LAESI Instruments, Software and Consumables, and Molecular Diagnostics and Clinical Research. Its services enable the identification and quantitation of both small molecules (lipids and metabolites) and large molecules (proteins) and the services portfolio, inclusive of mass spectrometry imaging (MSI), proteomics, metabolomics, lipidomics and bioinformatics. Its clients include pharmaceutical, chemical and biotechnology companies.

Sector

Healthcare Facilities & Services

More about the company

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
SONIC HEALTHCARE LIMITED	-24.63%	7.83B
RADNET, INC.	+70.30%	4.32B
DR. LAL PATHLABS LIMITED	+1.53%	2.63B
SYNLAB AG	-7.18%	2.53B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-44.62%	2.29B
NEOGENOMICS, INC.	-12.05%	1.82B
FLEURY S.A.	-19.84%	1.51B
METROPOLIS HEALTHCARE LIMITED	+18.85%	1.22B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-43.60%	1.17B

Medical & Diagnostic Laboratories